|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02561 VISEN PHARMA-B
Nominal 
34.000 +0.500 (+1.493%) Ranking Overview
Ranking based on 1 research report(s)
Average Ranking 2.00
|
Strong Buy (1)
0
|
Buy (2)
1
|
Hold (3)
0
|
Sell (4)
0
|
Strong Sell (5)
0
|
Previous Financial Performance
| Financial Year | 12/2024 | EPS | -- RMB (cts) | |
| Net Profit | -182.24 RMB (MIL) | DPS | -- RMB (cts) |
Consolidation Estimation
| Financial Year | Profit / (Loss) (RMB (MIL)) |
EPS/ ((LPS)(RMB (cts)) |
DPS (RMB (cts)) |
Net Asset Value per Share (RMB) |
Highest (RMB (MIL)) |
Lowest (RMB (MIL)) |
| 2025 | -167.00 | -147.00 | -- | -167.00 | -167.00 | |
| 2026 | -99.00 | -87.00 | -- | -99.00 | -99.00 | |
| 2027 | -58.00 | -51.00 | -- | -58.00 | -58.00 |
Profit Estimation
| Profit Estimation | Profit / (Loss) (RMB (MIL)) |
EPS*/ (LPS) (RMB (cts)) |
DPS * (RMB (cts)) |
Broker | Ranking | Target Price* (HKD) |
Update Date | |
| 2025 | -167.00 | -147.00 | -- | CITIC SEC | Buy | 51.00 | 29/01/2026 | |
| 2026 | -99.00 | -87.00 | -- | CITIC SEC | -- | -- | 29/01/2026 | |
| 2027 | -58.00 | -51.00 | -- | CITIC SEC | -- | -- | 29/01/2026 | |
| Remarks: | Average rating ranges from 1 to 5. The lower the figure, the higher the rating and the vice versa. |
| *EPS, DPS and Estimated Price would be adjusted upon Consolidation, Split and Bonus Issue | |
| Real time quote last updated: 30/01/2026 17:59 | |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -118,020 |
| %Change | 41.390% |
| EPS / (LPS) | RMB -1.180 |
| NBV Per Share (¥) | RMB 7.510 |